Veolia Water Solutions & Technologies (VWS), a provider of water treatment, is a design and build company and a provider of solutions for pharmaceutical and biotech clients.
Recently awarded by Frost & Sullivan the 2008 European Pharmaceutical Water & Wastewater Treatment Business Development Strategy Leadership prize, VWS will design and commission a wastewater treatment plant at 700 cu meters/day to treat effluents from a pharmaceutical drug manufacturing site in Singapore. The plant consists of two technologies, an AnoxKaldnes MBBR biological treatment and an Actiflo clarification unit.
The client has awarded VWS a contract to enhance and build a new wastewater treatment plant for its facility in Singapore. AnoxKaldnes MBBR is a compact moving bed biofilm reactor that operates continuously using specific plastic media to grow biofilm, and provides biochemical oxygen demand removal capability as well as ammonia and nitrogen removal.
Downstream the AnoxKaldnes MBBR, Actiflo, the sand-ballasted clarification and flocculation treatment process (a VWS patented technology), will act as final sludge separation and effluent discharge. Actiflo also provides a footprint up to 20 times smaller than conventional clarification systems with similar capacity, according to the company.
The plant has been designed with an odor treatment system using activated carbon for treating gases before release to the atmosphere.
